Emerging Immunotherapies for Parkinson Disease

Area of Science:

• Neuroscience
• Immunology
• Neurology

Background:

• Symptomatic treatments for Parkinson disease (PD) have advanced, but causal, disease-modifying therapies remain elusive.
• Alpha-synuclein (α-syn) pathology is central to PD pathogenesis, spreading throughout the central nervous system (CNS).
• Recent discoveries highlight the significant role of immune responses and neuroinflammation in PD progression.

Purpose of the Study:

• To review the pathomechanistic role of alpha-synuclein and its impact on the cellular environment, focusing on immune responses.
• To critically evaluate novel immunotherapeutic strategies aimed at reducing alpha-synuclein burden in the CNS.
• To present current human clinical trials for Parkinson disease immunotherapies.

Main Methods:

• Literature review focusing on alpha-synuclein, neuroinflammation, and immune responses in Parkinson disease.
• Analysis of pathomechanisms involving alpha-synuclein aggregation and spread.
• Evaluation of preclinical and clinical data for immunotherapeutic approaches.

Main Results:

• Immunologic technologies have demonstrated efficacy in preventing alpha-synuclein pathology progression in animal models.
• Novel immunotherapies targeting alpha-synuclein are now in early-stage human clinical trials.
• These approaches represent a new avenue for developing causal therapies for Parkinson disease.

Conclusions:

• Understanding the interplay between alpha-synuclein pathology and immune responses is crucial for developing effective Parkinson disease treatments.
• Emerging immunotherapies hold significant potential for modifying Parkinson disease progression.
• Rapid clinical development offers hope for a future causal therapy for Parkinson disease.